Published in APMIS on October 01, 2007
Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 3.14
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Genetic risk factors for melanoma. Hum Genet (2009) 1.21
Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene (2010) 1.13
Aberrant DNA methylation in malignant melanoma. Melanoma Res (2010) 1.04
Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res (2010) 1.03
Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul (2009) 1.03
CTGF is a therapeutic target for metastatic melanoma. Oncogene (2013) 1.00
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer (2011) 0.99
SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys (2014) 0.98
The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics (2012) 0.95
KIT is a frequent target for epigenetic silencing in cutaneous melanoma. J Invest Dermatol (2014) 0.91
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
Update on primary head and neck mucosal melanoma. Head Neck (2015) 0.88
Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies. J Cell Mol Med (2009) 0.88
Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics (2011) 0.86
Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol (2013) 0.85
Gender-Based Differences and Barriers in Skin Protection Behaviors in Melanoma Survivors. J Skin Cancer (2016) 0.85
Epigenetic biomarkers in skin cancer. Cancer Lett (2012) 0.84
NS398 induces apoptosis in non-small cell lung cancer cells. J Cancer Res Clin Oncol (2011) 0.81
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma. Open Cancer J (2011) 0.81
Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus. Oncotarget (2014) 0.80
Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance. Oncotarget (2015) 0.77
GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. PeerJ (2013) 0.77
Non-traditional melanoma prevention strategies in the young adult and adolescent population. Dermatol Pract Concept (2014) 0.77
The air liquid-interface, a skin microenvironment, promotes growth of melanoma cells, but not their apoptosis and invasion, through activation of mitogen-activated protein kinase. Acta Histochem Cytochem (2010) 0.77
Molecular dermatopathology in malignant melanoma. Dermatol Res Pract (2011) 0.77
Metastatic melanoma mimicking solitary fibrous tumor: report of two cases. Virchows Arch (2014) 0.76
Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development. Pharmaceuticals (Basel) (2010) 0.76
Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985-2013. Radiat Oncol (2016) 0.75
Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi. Cancers (Basel) (2015) 0.75
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn (2012) 2.53
Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene (2004) 2.47
Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol (2006) 1.55
Advances in DNA methylation: 5-hydroxymethylcytosine revisited. Clin Chim Acta (2011) 1.54
DNA methylation analysis techniques. Biogerontology (2003) 1.52
Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol (2007) 1.46
Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res (2005) 1.44
Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis. Mol Hum Reprod (2011) 1.42
Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res (2005) 1.41
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget (2013) 1.32
Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene (2004) 1.31
Genetic risk factors for melanoma. Hum Genet (2009) 1.21
Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene (2005) 1.20
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer (2010) 1.13
Immunogenicity of constitutively active V599EBRaf. Cancer Res (2004) 1.12
The challenges of comparing a clinically validated test to other methods. J Mol Diagn (2013) 1.09
Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol (2014) 1.05
Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene (2004) 1.05
ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood (2002) 0.97
The heritability of G2 chromosomal radiosensitivity and its association with cancer in Danish cancer survivors and their offspring. Int J Radiat Biol (2010) 0.97
A homogeneous assay for analysis of FMR1 promoter methylation in patients with fragile X syndrome. Clin Chem (2007) 0.95
Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer (2004) 0.95
Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms. Mod Pathol (2008) 0.94
A ligation assay for multiplex analysis of CpG methylation using bisulfite-treated DNA. Nucleic Acids Res (2007) 0.93
Chromosome analysis in childhood cancer survivors and their offspring--no evidence for radiotherapy-induced persistent genomic instability. Mutat Res (2005) 0.91
Towards discovery-driven translational research in breast cancer. FEBS J (2005) 0.90
Molecular analysis in Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22, MPZ, and Cx32/GJB1 mutations. Hum Mutat (2002) 0.89
Dopa-responsive dystonia and Tourette syndrome in a large Danish family. Arch Neurol (2003) 0.89
DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J Oral Pathol Med (2002) 0.88
A pilot study examining germline minisatellite mutations in the offspring of Danish childhood and adolescent cancer survivors treated with radiotherapy. Int J Radiat Biol (2006) 0.87
Role of fibulin-5 in metastatic organ colonization. Mol Cancer Res (2011) 0.87
Prediagnostic telomere length and risk of B-cell lymphoma-Results from the EPIC cohort study. Int J Cancer (2014) 0.86
Germline minisatellite mutations in survivors of childhood and young adult cancer treated with radiation. Int J Radiat Biol (2010) 0.86
High-resolution melting for accurate assessment of DNA methylation. Clin Chem (2007) 0.85
Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol Cell Proteomics (2003) 0.84
Aberrantly methylated DNA as a biomarker in breast cancer. Int J Biol Markers (2013) 0.83
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARβ signaling. Mol Cancer Res (2013) 0.81
Promoter hypermethylation of the retinoic acid receptor beta2 gene is frequent in acute myeloid leukaemia and associated with the presence of CBFbeta-MYH11 fusion transcripts. Br J Haematol (2006) 0.81
Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Basic Clin Pharmacol Toxicol (2008) 0.80
Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome. Pediatrics (2003) 0.80
Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11;18) in primary cutaneous MALT-type lymphoma. J Pathol (2003) 0.80
Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. Cancer Immunol Immunother (2005) 0.79
Duplication-dependent CG suppression of the seed storage protein genes of maize. Genetics (2003) 0.78
Behavioural effects of phenylalanine-free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria. Acta Paediatr (2005) 0.78
A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma? J Clin Pathol (2013) 0.77
Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer. J Mol Diagn (2010) 0.77
Genetic diversity within the R408W phenylketonuria mutation lineages in Europe. Hum Mutat (2003) 0.76
Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol (2005) 0.75
Author's reply: To PMID 23159593. J Mol Diagn (2013) 0.75
Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex. Mol Genet Metab (2005) 0.75
Cancer genomics. APMIS (2007) 0.75
Methods for detection of subtle mutations in cancer genomes. Crit Rev Oncog (2006) 0.75
[Acquired mutations--basic cancer biology]. Ugeskr Laeger (2006) 0.75
Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL. Eur J Haematol (2005) 0.75